Cardiac Amyloidosis 对比 AntiCoagAF 的使用情况和统计数据

All Cardiac Amyloidosis enthusiasts unite! Here is an app which can simplify staying abreast with the updates on the field and having a pocket guide to diagnosis based on the current data. Developed solely for educational purposes. The app does not substitute your physician's recommendations. Please refer to your physician for any healthcare related questions or treatment recommendations.
  • Apple 应用商店
  • 免费
  • 医疗

商店排名

- -

This application is for medical practitioners who need to quickly review which anticoagulant (including the direct oral anticoagulants (DOACs)) to use to prevent stroke in patients with non-valvular atrial fibrillation (NVAF). It contains relevant information about warfarin, apixaban, dabigatran, rivaroxaban and edoxaban. Topics covered include: comparison of anticoagulants, patient information, when anticoagulation is required, risk-benefit issues, when warfarin is appropriate, how to choose the dose of a DOAC, starting or switching between anticoagulants, edoxban information, clinical monitoring, bleeding risks, use of antiplatelet agents in addition to oral anticoagulants, managing ischemic strokes on DOACs, reversing anticoagulation in the event of intracerebral haemorrhage, a Cookcroft-Gault creatinine clearance calculator and peri-operative management information. Information contained within the application was edited by Dr Bruce Campbell. Coding was by CereScape (www.cerescape.com). It is our aim to keep this information current, and we welcome constructive comments and evidenced updated information. Any profit generated by this application will be used to fund stroke research.
  • Apple 应用商店
  • 付费
  • 医疗

商店排名

- -

Cardiac Amyloidosis与AntiCoagAF排名比较

对比 Cardiac Amyloidosis 与 AntiCoagAF 在过去 28 天内的排名趋势

排名

没有可用的数据

Cardiac Amyloidosis 对比 AntiCoagAF 的排名,按国家/地区比较

对比 Cardiac Amyloidosis 与 AntiCoagAF 在过去 28 天内的排名趋势

无数据可显示

通过免费试用版比较任何网站

开始使用
Cardiac Amyloidosis VS.
AntiCoagAF

十二月 19, 2024